These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1112 related articles for article (PubMed ID: 9732398)

  • 21. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
    Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
    J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
    Dekeyne A; Rivet JM; Gobert A; Millan MJ
    Neuropharmacology; 2001 Jun; 40(7):899-910. PubMed ID: 11378160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.
    Lejeune F; Millan MJ
    Synapse; 1998 Oct; 30(2):172-80. PubMed ID: 9723787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
    Newman-Tancredi A; Cussac D; Audinot V; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):447-53. PubMed ID: 10431754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol.
    Cussac D; Newman-Tancredi A; Nicolas JP; Boutin JA; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):549-54. PubMed ID: 10832610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
    Millan MJ; Canton H; Gobert A; Lejeune F; Rivet JM; Bervoets K; Brocco M; Widdowson P; Mennini T; Audinot V
    J Pharmacol Exp Ther; 1994 Jan; 268(1):337-52. PubMed ID: 8301575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
    Newman-Tancredi A; Gavaudan S; Conte C; Chaput C; Touzard M; Verrièle L; Audinot V; Millan MJ
    Eur J Pharmacol; 1998 Aug; 355(2-3):245-56. PubMed ID: 9760039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
    Newman-Tancredi A; Verrièle L; Touzard M; Millan MJ
    Eur J Pharmacol; 2001 Oct; 428(2):177-84. PubMed ID: 11675034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
    Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
    Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE; Janssen PM; Megens AA; Schotte A
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
    Hertel P
    Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.